Login to Your Account



PALOMA-3 proves Ibrance late-stage mettle for Pfizer, though impact likely small

By Randy Osborne
Staff Writer

Wednesday, April 15, 2015
It might not add much to Pfizer Inc.'s bottom line, since oral Ibrance (palbociclib) is approved already as a first-line therapy, but the first randomized phase III data with the compound made a strong showing in the trial called PALOMA-3.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription